- Trial phase
- Preclinical
- Time to market
- Unknown, at least 5-7 years if clinical development begins, given the preclinical stage and the company's constrained financial resources.
- Why 1/10
- RP1208 is a preclinical-stage asset with no scheduled clinical or regulatory catalyst in the next 12 months. It is a secondary program behind brilaroxazine at a company that has been delisted to OTC and faces significant financing challenges. Even a positive preclinical announcement would have minimal impact on RVPH's stock relative to the lead brilaroxazine program.
RP1208 is preclinical and has no scheduled clinical or regulatory catalyst in the next 12 months. For RVPH investors, the stock's trajectory depends entirely on the lead asset brilaroxazine (RP5063) and the company's ability to finance its Phase 3 RECOVER-2 trial. RP1208 is not a near-term value driver.
Price Chart
Executive Summary
RP1208 is a preclinical-stage, small-molecule triple reuptake inhibitor being developed by Reviva Pharmaceuticals Holdings (RVPH, OTCQB) for depression and obesity. It is a secondary pipeline asset behind the company's lead candidate brilaroxazine (RP5063), which is in Phase 3 for schizophrenia. RP1208 has composition-of-matter patents granted in the US, Europe, Canada, China, and Japan, but has not yet entered human clinical trials. Reviva itself is in a precarious financial position, delisted from Nasdaq to OTCQB in mid-2026, with a stock price around $0.54 (down from a 52-week high of $17.20) and roughly $20M in cash. RP1208 represents a long-shot, early-stage pipeline option with no near-term binary catalyst, making it a negligible factor for RVPH's near-term stock performance.
How It Works
RP1208 is a small-molecule triple reuptake inhibitor (TRI). It works by blocking the reuptake (reabsorption) of three key brain chemicals, serotonin, norepinephrine, and dopamine, thereby increasing their levels in the brain. This mechanism is similar to how some antidepressants work, but RP1208 targets all three neurotransmitters simultaneously, which could potentially offer broader efficacy for depression and also affect appetite regulation for obesity.
Trial Status
RP1208 is in preclinical development and has not yet entered human clinical trials. The company has completed preclinical pharmacology studies and secured composition-of-matter patents globally, but no IND filing or Phase 1 trial has been announced.
The Two-Sided Case
Upcoming Catalysts
- No near-term catalysts, RP1208 is preclinical with no announced IND filing or clinical trial start date.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Reviva Pharmaceuticals PRESS-RELEASE RVPH ·Originating report